WallStSmart

Revvity Inc. (RVTY)vsThermo Fisher Scientific Inc (TMO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 1460% more annual revenue ($44.56B vs $2.86B). TMO leads profitability with a 15.0% profit margin vs 8.5%. RVTY appears more attractively valued with a PEG of 0.53. RVTY earns a higher WallStSmart Score of 63/100 (C+).

RVTY

Buy

63

out of 100

Grade: C+

Growth: 4.7Profit: 5.5Value: 7.3Quality: 5.5
Piotroski: 4/9

TMO

Buy

59

out of 100

Grade: C

Growth: 4.7Profit: 7.0Value: 7.3Quality: 6.3
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

RVTYSignificantly Overvalued (-83.1%)

Margin of Safety

-83.1%

Fair Value

$55.21

Current Price

$87.84

$32.63 premium

UndervaluedFair: $55.21Overvalued
TMOSignificantly Overvalued (-27.5%)

Margin of Safety

-27.5%

Fair Value

$384.82

Current Price

$490.77

$105.95 premium

UndervaluedFair: $384.82Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RVTY3 strengths · Avg: 8.7/10
Price/BookValuation
1.4x10/10

Reasonable price relative to book value

PEG RatioValuation
0.538/10

Growing faster than its price suggests

Operating MarginProfitability
20.1%8/10

Strong operational efficiency at 20.1%

TMO3 strengths · Avg: 8.3/10
Market CapQuality
$182.14B9/10

Large-cap with strong market position

Operating MarginProfitability
21.2%8/10

Strong operational efficiency at 21.2%

Free Cash FlowQuality
$2.99B8/10

Generating 3.0B in free cash flow

Areas to Watch

RVTY2 concerns · Avg: 2.5/10
Return on EquityProfitability
3.2%3/10

ROE of 3.2% — below average capital efficiency

P/E RatioValuation
42.5x2/10

Premium valuation, high expectations priced in

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.764/10

Expensive relative to growth rate

P/E RatioValuation
27.6x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : RVTY

The strongest argument for RVTY centers on Price/Book, PEG Ratio, Operating Margin. PEG of 0.53 suggests the stock is reasonably priced for its growth.

Bull Case : TMO

The strongest argument for TMO centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : RVTY

The primary concerns for RVTY are Return on Equity, P/E Ratio. A P/E of 42.5x leaves little room for execution misses.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

RVTY carries more volatility with a beta of 1.11 — expect wider price swings.

TMO is growing revenue faster at 7.2% — sustainability is the question.

TMO generates stronger free cash flow (3.0B), providing more financial flexibility.

Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RVTY scores higher overall (63/100 vs 59/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Revvity Inc.

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets globally. The company is headquartered in Waltham, Massachusetts.

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Want to dig deeper into these stocks?